Literature DB >> 17979599

Emerging drugs for cancer cachexia.

Josep M Argilés1, Francisco J López-Soriano, Sílvia Busquets.   

Abstract

Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion and muscle protein catabolism among others. The altered metabolic status generates a high degree of energetic inefficiency that results in weight loss, fatigue and a considerable loss of muscle and, therefore, asthenia. The aim of the present article is to review the different therapeutic approaches and emerging drugs that have been designed to fight and counteract cachexia associated with cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979599     DOI: 10.1517/14728214.12.4.555

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  1 in total

1.  Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

Authors:  C A Greig; N Johns; C Gray; A MacDonald; N A Stephens; R J E Skipworth; M Fallon; L Wall; G M Fox; K C H Fearon
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.